Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Angelos M. Stergiou M.D., ScD h.c. |
Contact Details
Address: 7 Times Square, Suite 2503 New York, New York 10036 United States | |
| Phone | (646) 200-5278 |
| Website | sellaslifesciences.com |
Stock Details
| Ticker Symbol | SLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001390478 |
| CUSIP Number | 81642T209 |
| ISIN Number | US81642T2096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer and Director |
| John Thomas Burns CPA | Senior Vice President and Chief Financial Officer |
| Stacy E. Yeung | Vice President, Associate General Counsel and Head of Compliance |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development |
| Andrew Elnatan | Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | EFFECT | Notice of Effectiveness |
| May 1, 2024 | EFFECT | Notice of Effectiveness |
| Apr 30, 2024 | ARS | Filing |
| Apr 29, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | UPLOAD | Filing |